Episode Details

Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. | Case No. 24-889 | Docket Link: Here | Argued: 04/29/2026 | Decided: 06/04/2026

Overview: Amarin's cardiovascular drug patent faced challenge when generic maker Hikma launched a skinny-label version and marketed it through statements Amarin claimed encouraged doctors to prescribe the generic for the still-patented heart indication.

Question Presented: Whether a generic drug maker's marketing statements plausibly constitute "active steps" inducing patent infringement under 35 U.S.C. §271(b).

Posture: District Court dismissed; Federal Circuit reversed; Supreme Court reversed and remanded.

Main Arguments:

Petitioner (Hikma):

• (1) Statements fully consistent with lawful skinny-label marketing cannot constitute active inducement under §271(b);
• (2) Federal law mandated the label's contents, making legal compliance an obvious alternative explanation that forecloses liability;
• (3) The Federal Circuit's physician-reading standard would destroy the Hatch-Waxman section viii pathway and expose generics to devastating litigation risk.

Respondent (Amarin):

• (1) Hikma's totality of statements — repeatedly invoking "generic Vascepa," using an overbroad therapeutic category, and touting Vascepa's billion-dollar sales — plausibly encouraged infringing use;
• (2) Amarin spent $300 million discovering the cardiovascular indication and patent law must protect that investment from free-riders;
• (3) Seven other generic manufacturers avoided liability by accurately describing only their narrow approved uses, demonstrating Hikma's conduct fell outside normal practice.

Holding: Amarin failed to state a claim for active inducement in violation of §271(b); none of Hikma's alleged statements — individually or in totality — plausibly constituted active steps encouraging infringement of Amarin's cardiovascular-use patents.

Voting Breakdown: 9-0. Justice Jackson delivered the opinion for a unanimous Court. No Justice filed a separate opinion. Federal Circuit reversed and remanded.

Opinion: Here

Majority Reasoning:

• (1) Active inducement requires affirmative steps to encourage infringement — not merely statements physicians could read as instructions to infringe;
• (2) Hikma's label reflected legal compliance under the duty of sameness, its "generic Vascepa" description reflected standard industry practice, and omissions alone cannot support active inducement;
• (3) Website category descriptions, patient leaflet warnings, and investor press release sales figures lacked the clear, affirmative message inducement demands.

Separate Opinions: None. The decision was unanimous.

Implications:

• (1) Generic manufacturers may use the Hatch-Waxman skinny-label pathway without automatic inducement liability for routine commercial communications;
• (2) Brand manufacturers must plead specific affirmative acts of encouragement — not inferences drawn from vague statements or omissions;
• (3) The active inducement framework now applies with fresh clarity across all patent-holding industries.

The Fine Print:

• 35 U.S.C. §271(b): "Whoever actively induces infringement of a patent shall be liable as an infringer."
• 21 U.S.C. §355(j)(2)(A)(v): Requires a generic drug application to contain "information to show that the labeling proposed for the new drug is the same as the l